Evotec SE Stock: price and insider trades · Germany

Every trade that managers of Evotec SE disclose to BaFin is tracked on this page. The company sits in the Healthcare & Pharma sector and is based in Hamburg, Germany. It was founded in 1993. Between 18 October 2025 and 18 October 2026, 6 insiders published 13 filings.

Purchases and sales both appear in the filings: 3 purchases (3 insiders, €172k) and 4 sales (1 insider, €901k). Netting one side against the other leaves €730k of net selling. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The buyers include 2 board members and 1 senior executive. Dohrmann, Dr. Cord filed the largest sale, €577k, on 17 June 2026, which represents 0.098% of the company's market value.

For context, the typical company on the same exchange (median of 287 companies) published 5 filings over the same period, against 13 filings here. Looking back to 2025, when coverage begins, insiders filed 5 purchases and 4 sales.

In all, 2 purchases were made within 30 days of a purchase by another insider of the company. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The latest purchase dates back some time: it was published 312 days ago, on 9 December 2025. Typically, a trade is published a median of 1 day after it takes place. The regulation allows three business days to notify a trade (MAR article 19). Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.

Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Anixa Biosciences Inc. This summary is built from BaFin disclosures alone and does not predict where the share price will go.